Abstract
The use of genetically modified cells to deliver growth factors has been proposed as a possible treatment for neurodegeneration, including Parkinson’s disease. Here we demonstrate that the implantation of fibroblasts genetically modified to secrete fibroblast growth factor-1 (FGF) increased striatal dopamine concentrations in a l-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine (MPTP)-treated mouse model of Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
References
Bankiewicz, K.S., Leff, S.E., Nagy, D., Jungles, S., Rokovich, J., Spratt, K., Cohen, L., Libonati, M., Snyder, R.O., Man-del R.J. (1997) Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson’s disease. Exp. Neurology144, 147–56.
Beck, K.D., Knusel, B. & Hefti, F. (1990) The nature of the trophic action of brain-derived neurotrophic factor, des (l-3)-insulin-like growth factor-1 and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience10, 1912–1921.
Chase, T.N., Engber, T.M. & Mouradian, M.M. (1993) Striatal dopamioceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson’s disease. Adv Neurol60, 181–185.
Date, I., Notter, M.F., Felten, S.Y. & Felten, D.L. (1990) MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by sterotaxic injection of acidic fibroblast growth factor (aFGF). Brain Res526, 156–160.
Engle, J. & Bohn, M.C. (1991) The neurotrophic effects of fibroblast growth factor on dopaminergic neurons in vitro are mediated by mesencephalic glia. J Neurosci11, 3070–3078.
Forough, R., Xi, Z., MacPhee, M, Friedman, S., Engleka, K.A., Sayers, T., Wiltrout, R.H. & Maciag, T. (1993) Differential transforming abilites of non-secreted and secreted forms of human fibroblast growth factor-1. J Biol Chem268, 2960–2968.
Gerlach, M, Riederer, P., Przuntek, H., Youdim, M.B. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur J Pharmacol208, 273–286.
Heikkila, R.E., Hess, A. & Duvoisin, R.C. (1984) Dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,5,6-tetrahy-dropyridine in mice. Science224, 1451–1453.
Horellou, P., Mallet, J. (1997) Gene therapy for Parkinson’s disease. Molec Neurobiol15, 241–256.
Olanow, C.W. (1997), Attempts to obtain neuroprotection in Parkinson’s disease. Neurology49, S26–33.
Otto, D. & Unsicker, K. (1990) Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci10, 1912–1921.
Pizzorusso, T., Porciatti, V., Tseng, J.L., Aebischer, P., Maffei, L., (1997) Transplant of polymer-encapsulated cells genetically engineered to release nerve growth factor allows a normal functional development of the visual cortex in dark-reared rats. Neuroscience80, 307–311.
Schneider, J.S. & Markham, C.H. (1986) Neurotoxic effects of N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in the cat. Brain Res373, 258–267.
Willing, A.E., Cameron D.F., Sanberg P.R. (1998) Sertoli cell transplants: their use in the treatment of neurodegenerative disease, Molec Med Today4, 471–477.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mclay, R.N., Freeman, S.M. & Zadina, J.E. Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice. neurotox res 3, 249–253 (2001). https://doi.org/10.1007/BF03033263
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF03033263